[April 17, 2014] |
|
SC Launch Portfolio Company Announces Acquisition
GREENVILLE, S.C. --(Business Wire)--
SCRA Technology Ventures today announced that portfolio company Selah
Genomics was sold to EKF Diagnostics, a publically-traded UK-based
diagnostics firm. Selah, a provider of advanced molecular and genomic
diagnostic services, completed the deal today, making it the largest of
nine exits out of the SC Launch program since 2006. In various forms
since 2007, Selah has received four rounds of investments from SCRA's SC
Launch and Stage 2 programs. EKF Diagnostics will acquire Selah for an
initial $40 million in stock, with an additional deferred consideration
of up to $35 million in shares, based upon future performance.
EKF will retain Selah's management team and plans to accelerate Selah's
growth. Selah will hire a national sales force to sell PrecisionPath®, a
test that helps physicians make treatment decisions for patients with
cancer by identifying the molecular growth drivers of their cancers. In
addition, Selah will launch a portfolio of cardiovascular disease and
obesity management assays recently licensed from Spanish firm Ferrer
InCode.
"SCRA Technology Ventures' investment programs have a strong history of
making successful placements in South Carolina's technology-based
companies, furthering the state's Knowledge Economy," said SCRA CEO Bill
Mahoney. "The Selah Genomics acquisition validates SCRA's continued
investment and support of the portfolio company and its management team.
Throughout the past seven years, we have enjoyed a wonderful
relationship with Selah and CEO Michael Bolick, and we congratuate him
on this accomplishment. We are delighted that Selah operations will
continue and grow in the state and look forward to many future
achievements. We are also very pleased that this outcome generates
returns not only for SCRA but also with co-investment partners, the
Upstate Carolina Angel Network, Nexus Medical Partners and the
Greenville Local Development Corporation."
"We are grateful for our long-standing relationship with SCRA Technology
Ventures. They have been an investor and supporter of ours from the
beginning. SCRA's SC Launch and Stage 2 programs respectively provided
early and mid-stage tranches of investment at critical points during our
company's life cycle. We are now blessed with an opportunity to make an
exciting return on those investments," said Selah Genomics CEO Michael
Bolick. This transaction is yet another example of how SCRA's programs
and their co-investment partners are successfully working together in
South Carolina."
About SCRA
http://www.scra.org/
SCRA Technology Ventures helps innovative companies grow and develop new
technologies, creating jobs and advancing the Knowledge Economy
throughout South Carolina. This SCRA business sector provides support
and mentoring program to early stage, start-up technology companies
through its flagship SC Launch. Since 2006, SCRA has deployed over $79
million in funding and infrastructure to support over 280 high-tech,
early-stage enterprises and has directly invested nearly $18 million in
South Carolina start-ups, attracting over $260 million in private
investment. SCRA Technology Ventures also supports commercialization and
growth by facilitating the transfer of intellectual property and
accelerating the transition of inventions to the marketplace.
Multiple economic impact studies show SCRA's cumulative output on South
Carolina's economy to be over $15.3 billion, and that the company has
helped create approximately 15,000 technology-related jobs in the state,
with annual wages averaging between $55,000 and $77,000.
About Selah Genomics
Selah Genomics is a clinical diagnostic specialist supporting healthcare
providers and the pharmaceutical industry with advanced molecular and
genomic diagnostic services. Selah's services add value to early stage
drug development, clinical trials and regulatory processes in the
pharmaceutical industry and helps clinicians and healthcare providers
treat and monitor patients, thereby improving patient outcomes.
With the Power of Precision, Selah Genomics provides the best in
molecular diagnostic testing, assay validation and genomic profiling
that all leads to one common goal: to provide better outcomes for
patients.
[ Back To TMCnet.com's Homepage ]
|